Skip to content

Study · Animal study (in vivo) · rat · 2022

5 results

Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.

Larsen AT, Mohamed KE, Sonne N, Bredtoft E, Andersen F, Karsdal MA, Henriksen K

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie12 Oct 2022Cited by 32 (Europe PMC)

PMID36242844 (opens in a new tab)DOI10.1016/j.biopha.2022.113842 (opens in a new tab)PepBankPUB-36242844
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat diet fed obese rats, cagrilintide induced potent, dose-dependent weight loss, but the highest dose of KBP-336 was superior to cagrilintide.

    In plain wordsIn obese rats, cagrilintide caused dose-dependent weight loss, but the highest dose of KBP-336 caused more weight loss.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight loss in high-fat diet fed rats
    Study

    ratn: not reported in source

    High-fat diet fed obese rats
    Comparator
    KBP-336
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KBP-336 and cagrilintide induced a potent and dose-dependent weight loss in HFD rats, with the highest dose of KBP-336 being superior to cagrilintide.
    1 context sentence
    Summary · context
    In vivo efficacies on body weight and glucose homeostasis were investigated head-to-head in high-fat diet (HFD) fed obese and T2D (ZDF) rat models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ZDF rats, cagrilintide improved fasting blood glucose, but KBP-336 was superior in improving glucose control.

    In plain wordsIn diabetic rats, cagrilintide lowered fasting blood glucose, but KBP-336 improved glucose control more.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFasting blood glucose in ZDF rats
    Study

    ratn: not reported in source

    Diabetic ZDF rats
    Comparator
    KBP-336
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In diabetic ZDF rats, DACRA treatment improved fasting blood glucose
    2 context sentences
    Summary · context
    with KBP-336 being superior to cagrilintide in improving glucose control.
    Summary · context
    In vivo efficacies on body weight and glucose homeostasis were investigated head-to-head in high-fat diet (HFD) fed obese and T2D (ZDF) rat models.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ZDF rats, cagrilintide improved HbA1c levels, but KBP-336 was superior in improving glucose control.

    In plain wordsIn diabetic rats, cagrilintide lowered HbA1c, but KBP-336 improved glucose control more.

    Peptide
    Cagrilintide
    Outcome
    DecreaseHbA1c in ZDF rats
    Study

    ratn: not reported in source

    Diabetic ZDF rats
    Comparator
    KBP-336
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In diabetic ZDF rats, DACRA treatment improved fasting blood glucose, HbA1c levels, and insulin action, with KBP-336 being superior to cagrilintide in improving glucose control.
    1 context sentence
    Summary · context
    In vivo efficacies on body weight and glucose homeostasis were investigated head-to-head in high-fat diet (HFD) fed obese and T2D (ZDF) rat models.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ZDF rats, cagrilintide improved insulin action, but KBP-336 was superior in improving glucose control.

    In plain wordsIn diabetic rats, cagrilintide improved insulin action, but KBP-336 improved glucose control more.

    Peptide
    Cagrilintide
    Outcome
    IncreaseInsulin action in ZDF rats
    Study

    ratn: not reported in source

    Diabetic ZDF rats
    Comparator
    KBP-336
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In diabetic ZDF rats, DACRA treatment improved fasting blood glucose, HbA1c levels, and insulin action, with KBP-336 being superior to cagrilintide in improving glucose control.
    1 context sentence
    Summary · context
    In vivo efficacies on body weight and glucose homeostasis were investigated head-to-head in high-fat diet (HFD) fed obese and T2D (ZDF) rat models.
  5. 05LabIn vitro (cells)Activity measurement

    Cagrilintide activated both the amylin receptor and the calcitonin receptor in vitro and in vivo, and was less potent than KBP-336, which showed a calcitonin receptor bias.

    In plain wordsIn lab tests and rats, cagrilintide switched on amylin and calcitonin receptors, but less strongly than KBP-336.

    Peptide
    Cagrilintide
    Outcome
    Not applicableAmylin and calcitonin receptor activation
    Study

    n: not reported in source

    Comparator
    KBP-336
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides activate the amylin and the calcitonin receptor in vitro and in vivo, with KBP-336 being more potent, and showing a CTR bias.
    1 context sentence
    Summary · context
    In vivo efficacies on body weight and glucose homeostasis were investigated head-to-head in high-fat diet (HFD) fed obese and T2D (ZDF) rat models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    9 Oct 2026, 18:17 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.